In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

(2020) Kenneth V.I. Rolston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology of β-Lactamase-Producing Pathogens

(2020) Karen Bush et al.   CLINICAL MICROBIOLOGY REVIEWS

In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units

(2020) Alyssa R. Golden et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam against Clinical Isolates of Gram-Negative Bacilli with Difficult-to-Treat Resistance and Multidrug-Resistant Phenotypes – SMART United States 2015-2017

(2020) James A Karlowsky et al.   CLINICAL INFECTIOUS DISEASES

Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles Heel of the Trojan Horse?

(2020) Patricia J. Simner et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

(2020) Naoki Kohira et al.   Journal of Global Antimicrobial Resistance

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

(2019) Takafumi Sato et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

(2019) Yoshinori Yamano   CLINICAL INFECTIOUS DISEASES

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

(2018) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

(2017) J. Dobias et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals

(2017) Matthew E. Falagas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

252S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria

(2017) Masakatsu Tsuji et al.   Open Forum Infectious Diseases

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity againstPseudomonas aeruginosa

(2016) Akinobu Ito et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

(2015) Naoki Kohira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY